038 Stock Chart & Stats
€14.97
-€0.71(-4.58%)
At close: 4:00 PM EDT
€14.97
-€0.71(-4.58%)
Day’s Range― - ―
52-Week Range€8.12 - €17.24
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€1.53B
Enterprise Value€1.54B
Total Cash (Recent Filing)€440.56M
Total Debt (Recent Filing)€233.42M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Oct 29, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding116,445,840
10 Day Avg. Volume5
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.23
Price to Sales (P/S)2.20
P/FCF Ratio-19.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€30.04Price Target Upside100.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.1
Revenue Forecast (FY)€647.85M
Bulls Say, Bears Say
Bulls Say
Revenue And Patient GrowthGrowing revenue alongside active-patient expansion indicates broader utilization of NovoCure’s therapy platform, not merely pricing or accounting effects. Continued patient growth can support recurring therapy-related revenue and strengthen the commercial base across established markets.
Improving Margins And Operating DisciplineThe sharp improvement in gross margin and adjusted EBITDA shows operating leverage emerging as revenue scales and costs are managed. If mid-70s margins and disciplined R&D and G&A spending persist, NovoCure could move closer to sustainable profitability.
Regulatory Expansion In JapanJapanese approval expands Optune Pax into a major international market and validates its clinical benefit in a difficult cancer setting. The new indication broadens NovoCure’s addressable opportunity and may create a durable channel for adoption beyond existing geographies.
Bears Say
Persistent Losses And Cash BurnDespite better quarterly results, NovoCure remains materially loss-making and free-cash-flow negative on a trailing basis. Continued cash burn can restrict funding flexibility for launches and clinical programs, while prolonged losses could weaken the balance sheet if improvement stalls.
Reimbursement And Access BarriersMarket access depends on reimbursement decisions, contracting and local treatment rules, which can delay patient starts even after regulatory approval. These hurdles may slow international uptake, lengthen commercialization timelines and make revenue growth less predictable across regions.
Clinical Execution And Adoption RisksThe company must convert initial Optune Pax interest into repeat prescribing while also managing changes to the LUNAR-2 trial. Failure to improve persistence or preserve clinical momentum could limit product growth and delay evidence needed for future expansion.
NovoCure News
038 FAQ
What was NovoCure Ltd’s price range in the past 12 months?
NovoCure Ltd lowest stock price was €8.12 and its highest was €17.24 in the past 12 months.
What is NovoCure Ltd’s market cap?
NovoCure Ltd’s market cap is €1.53B.
When is NovoCure Ltd’s upcoming earnings report date?
NovoCure Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 14 days.
How were NovoCure Ltd’s earnings last quarter?
NovoCure Ltd released its earnings results on Jul 23, 2026. The company reported -€0.116 earnings per share for the quarter, beating the consensus estimate of -€0.296 by €0.18.
Is NovoCure Ltd overvalued?
According to Wall Street analysts NovoCure Ltd’s price is currently Undervalued.
Does NovoCure Ltd pay dividends?
NovoCure Ltd does not currently pay dividends.
What is NovoCure Ltd’s EPS estimate?
NovoCure Ltd’s EPS estimate is -0.21.
How many shares outstanding does NovoCure Ltd have?
NovoCure Ltd has 116,445,840 shares outstanding.
What happened to NovoCure Ltd’s price movement after its last earnings report?
NovoCure Ltd reported an EPS of -€0.116 in its last earnings report, beating expectations of -€0.296. Following the earnings report the stock price went up 23.502%.
Which hedge fund is a major shareholder of NovoCure Ltd?
Currently, no hedge funds are holding shares in DE:038
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovoCure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€30.04 (100.69% Upside)
€30.04 (100.69% Upside)
Blogger Sentiment
Bullish
DE:038 Sentiment 78%
Sector Average 67%
Sector Average 67%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.00%
12-Months-Change
Fundamentals
Return on Equity
-44.00%
Trailing 12-Months
Asset Growth
-36.17%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NovoCure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
038 Company Deck
038 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial commercial momentum highlighted by record net revenue (+16% YoY), active patient growth (Optune Gio +11% YoY), successful early launches (Optune Pax and Optune Lua), and a return to positive adjusted EBITDA in the quarter. Management also emphasized disciplined cost-management actions (R&D reductions and LUNAR-2 optimization) and updated full-year guidance reflecting confidence in continued progress. Key challenges include reimbursement and contracting hurdles (EU and Japan), reliance on some one-time benefits in Q2, the need to convert one-time prescribers into repeat prescribers for sustained growth, and clinical trial redesign risks. Overall, the positives — stronger commercial performance, profitability trajectory, regulatory milestones and clear launch progress — meaningfully outweigh the identified lowlights.View all DE:038 earnings summaries038 Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
038 Stock 12 Month Forecast
Average Price Target
€30.04
▲(100.69% Upside)
Technical Analysis
Accuray
―
Delcath Systems
―
Perspective Therapeutics
―
Sensus Healthcare
―
TriSalus Life Sciences
―